Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

BCRX vs CVM: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

BCRX Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 7–3 Matrix Metrics)

BCRX Overall Winner 6-Pillar Tally: BCRX 6 – 0 CVM Matrix Metrics: BCRX 7 – 3 CVM

As of Nov 16, 2026, BioCryst Pharmaceuticals Inc (BCRX) is the stronger overall head-to-head candidate over Cel-Sci Corporation (CVM) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BCRX carries a Unified Composite Score of 43.3/100 (HOLD) at $7.53 (8.9x Forward P/E, 48.8% operating margin), whereas CVM carries 56.6/100 (HOLD) at $1.59 (23.0x Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While CVM currently prints a higher short-term Unified Composite Score (56.6/100 HOLD vs. BCRX 43.3/100 HOLD), BCRX captures the overall institutional head-to-head verdict (7–3 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (48.8% vs. 0.0% operating margin) and revenue trajectory (+13.1% vs. -62.7% YoY).
  • Technical & Structure Timing Caution: BCRX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 39.3); meanwhile CVM is in a Breakdown options structure phase (RSI 57.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About BCRX vs CVM
BCRX NASDAQ Head-to-Head Winner
BioCryst Pharmaceuticals Inc
Biological Products, (No Disgnostic Substances)
$7.53
-1.05% 1D
Market Cap $1.9B
TTM Revenue $962M
Forward P/E 8.9x
Beta / 30D Vol 0.77β · 42% Vol
Unified Composite Score
43.3 / 100 HOLD
Tech 24.0 Fund 59.0 Flow 67.0 Mom 68.9
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -8.8%), weak momentum, RSI 39
RSI-14: 39.3 · SMA20: $7.92 · SMA50: $8.18
CVM NYSE American
Cel-Sci Corporation
Biological Products, (No Disgnostic Substances)
$1.59
+24.22% 1D
Market Cap $20.9M
TTM Revenue $28,558
Forward P/E 23.0x
Beta / 30D Vol 0.65β · 120% Vol
Unified Composite Score
56.6 / 100 HOLD
Tech 60.0 Fund 54.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 57
RSI-14: 57.1 · SMA20: $1.46 · SMA50: $1.66

6-Pillar Scorecard Institutional Category Breakdown (BCRX 6 – 0 CVM)

Columns: Metric · BCRX · CVM
1. Valuation Multiples BCRX
Forward P/E 8.9x 23.0x
Trailing P/E 13.0x 23.0x
PEG Ratio 9.39x 1.12x
EV / Revenue 2.7x N/M
2. Growth & Scale BCRX
Revenue Growth (YoY) +13.1% -62.7%
Earnings Growth (YoY) +133.3% +0.0%
TTM Revenue (USD) $962M $28,558
Market Cap $1.9B $20.9M
3. Profitability & Quality BCRX
Gross Margin 78.1% N/A
Operating Margin 48.8% 0.0%
Net Profit Margin -37.4% 0.0%
Return on Equity (ROE) -1925.4% -252.5%
4. Balance Sheet & Cash Flow BCRX
Cash Generation (TTM) $366M -$17M
Cash Flow Margin 38.0% N/A
Net Cash / Leverage $687M Net Debt $6.6M Net Debt (1.24x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning BCRX
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 60.0% (12th %ile) N/A (N/A)
Put/Call OI Skew 0.24x (Call-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Markdown NEUTRAL · Neutral
6. R&D & Supply-Chain Moat BCRX
OpEx & R&D Intensity 29.3% of Rev ($282M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Drug Manufacturers - Specialty & Generic Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: BCRX (7) vs CVM (3)
Institutional Metric BCRX CVM Criterion Row Edge
Market Capitalization
Scale
$1.9B $20.9M Larger Scale BCRX
Trailing P/E Ratio
Valuation
13.0x 23.0x Lower Multiple BCRX
Forward P/E Ratio
Valuation
8.9x 23.0x Lower Multiple BCRX
Revenue Growth (YoY)
Growth
+13.1% -62.7% Higher Growth BCRX
Operating Margin (TTM)
Profitability
48.8% 0.0% Higher Margin BCRX
Net Profit Margin
Profitability
-37.4% 0.0% Higher Margin CVM
Return on Equity (ROE)
Capital Efficiency
-1925.4% -252.5% Higher ROE CVM
52-Week Range Position
Momentum
26% ($6–$11) 10% ($1–$8) Stronger Trend BCRX
Beta / 30D Volatility
Risk Regime
0.77β · 42% Vol 0.65β · 120% Vol Lower Realized Risk BCRX
Unified Institutional Score
Composite Signal
43.3 / 100 (HOLD) 56.6 / 100 (HOLD) Higher Composite CVM
Trailing 12M Revenue (USD)
Operating Scale
$962M $28,558 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
78.1% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
9.39x PEG · 2.7x EV/Rev 1.12x PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$366M ($687M Net Debt) -$17M ($6.6M Net Debt (1.24x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon BCRX +7.83 pp
BCRX: -3.34% · CVM: -11.17%
3M Horizon CVM +22.37 pp
BCRX: -22.37% · CVM: +0.0%
6M Horizon CVM +8.49 pp
BCRX: -16.05% · CVM: -7.56%
1Y Horizon BCRX +82.34 pp
BCRX: +6.36% · CVM: -75.98%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period BCRX Revenue CVM Revenue BCRX Op. Margin CVM Op. Margin Margin Leader
FY2018 $20M N/A -456.2% N/A BCRX
FY2019 $50M N/A -203.7% N/A BCRX
FY2020 $20M N/A -981.1% N/A BCRX
FY2021 $160M N/A -113.1% N/A BCRX
FY2022 $270M N/A -54.8% N/A BCRX
FY2023 $330M N/A -31.3% N/A BCRX
FY2024 $450M N/A -0.6% N/A BCRX
FY2025 $870M N/A 39.0% N/A BCRX

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
BCRX BREAKDOWN
92d in phase · OBV DISTRIBUTION
Current IV 60.0%
IV Percentile 12th %ile
Put/Call OI Skew 0.24x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact BCRX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CVM BREAKDOWN
29d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CVM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
BCRX Moat Profile High-Margin Pricing Power Moat
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $1.9B market capitalization and 48.8% operating margin.
OpEx & R&D Reinvestment 29.3% of Rev ($282M)
90D Engineering Disclosures 0 Published
CVM Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $20.9M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ BCRX vs CVM Key Questions & Quantitative Answers

As of Nov 16, 2026, BioCryst Pharmaceuticals Inc (BCRX) is the stronger overall head-to-head candidate over Cel-Sci Corporation (CVM) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BCRX carries a Unified Composite Score of 43.3/100 (HOLD) at $7.53 (8.9x Forward P/E, 48.8% operating margin), whereas CVM carries 56.6/100 (HOLD) at $1.59 (23.0x Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While CVM currently prints a higher short-term Unified Composite Score (56.6/100 HOLD vs. BCRX 43.3/100 HOLD), BCRX captures the overall institutional head-to-head verdict (7–3 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (48.8% vs. 0.0% operating margin) and revenue trajectory (+13.1% vs. -62.7% YoY). Technical & Structure Timing Caution: BCRX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 39.3); meanwhile CVM is in a Breakdown options structure phase (RSI 57.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

BCRX leads the Growth & Scale pillar: BCRX posts +13.1% YoY revenue growth and +133.3% YoY earnings growth on $962M TTM revenue (78.1% gross margin, 48.8% operating margin), compared with CVM at -62.7% YoY revenue growth and +0.0% YoY earnings growth on $28,558 TTM revenue (N/A gross margin, 0.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), BCRX cumulative revenue shifted +4250.0% while CVM shifted N/A. In operating R&D and SG&A reinvestment, BCRX deploys 29.3% of Rev ($282M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CVM.

BCRX screens cheaper on headline valuation multiples. BCRX trades at 8.9x Forward P/E, 13.0x Trailing P/E, 9.39x PEG, and 2.7x EV/Revenue (38.0% FCF margin), whereas CVM trades at 23.0x Forward P/E, 23.0x Trailing P/E, 1.12x PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BCRX (-1925.4% ROE) versus CVM (-252.5% ROE) capital efficiency.

In options market volatility and institutional positioning, BCRX carries 60.0% implied volatility (12th %ile, Compressed (<25th %ile)), a 0.24x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.77β · 42% Vol realized risk). By comparison, CVM carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (0.65β · 120% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.